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ORIGINAL ARTICLES: ENDOMETRIOSISDeveloping symptom-based
predictive models of endometriosis
as a clinical screening tool: results
from a multicenter study
Kelechi E. Nnoaham,M.D.,a Lone Hummelshoj,b StephenH. Kennedy,M.R.C.O.G.,c Crispin Jenkinson, D.Phil.,d
and Krina T. Zondervan, D.Phil.,d,e on behalf of the World Endometriosis Research Foundation Women's
Health Symptom Survey Consortium
a Department of Public Health, University of Oxford, Oxford; b World Endometriosis Research Foundation, London;
c Nufﬁeld Department of Obstetrics & Gynaecology, University of Oxford, Oxford; d Health Services Research Unit,
University of Oxford, Oxford; and e Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United
KingdomObjective: To generate and validate symptom-based models to predict endometriosis among symptomatic women prior to undergoing
their ﬁrst laparoscopy.
Design: Prospective, observational, two-phase study, in which women completed a 25-item questionnaire prior to surgery.
Setting: Nineteen hospitals in 13 countries.
Patient(s): Symptomatic women (n ¼ 1,396) scheduled for laparoscopy without a previous surgical diagnosis of endometriosis.
Intervention(s): None.
Main Outcome Measure(s): Sensitivity and speciﬁcity of endometriosis diagnosis predicted by symptoms and patient characteristics
from optimal models developed using multiple logistic regression analyses in one data set (phase I), and independently validated in
a second data set (phase II) by receiver operating characteristic (ROC) curve analysis.
Result(s): Three hundred sixty (46.7%) women in phase I and 364 (58.2%) in phase II were diagnosed with endometriosis at
laparoscopy. Menstrual dyschezia (pain on opening bowels) and a history of benign ovarian cysts most strongly predicted both any
and stage III and IV endometriosis in both phases. Prediction of any-stage endometriosis, although improved by ultrasound scan
evidence of cyst/nodules, was relatively poor (area under the curve [AUC] ¼ 68.3). Stage III and IV disease was predicted with good
accuracy (AUC ¼ 84.9, sensitivity of 82.3% and speciﬁcity 75.8% at an optimal cut-off of 0.24).
Conclusion(s): Our symptom-based models predict any-stage endometriosis relatively poorly and stage III and IV disease with goodUse your smartphoneaccuracy. Predictive tools based on such models could help to prioritize women for surgical
investigation in clinical practice and thus contribute to reducing time to diagnosis. We invite
other researchers to validate the key models in additional populations. (Fertil Steril
2012;98:692–701. 2012 by American Society for Reproductive Medicine.)
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012.04.022the impaired quality of life and
signiﬁcant personal and societal costs
associated with the condition (5). Sur-
gery under general anaesthesia, most
commonly a laparoscopy, is required
to make a deﬁnitive diagnosis but this
is expensive and potentially associated
with complications (6, 7). The avail-
ability of a noninvasive method to
evaluate the likelihood of ﬁnding
endometriosis at laparoscopy could
reduce the diagnostic delay (8) and
the number of women undergoingVOL. 98 NO. 3 / SEPTEMBER 2012
Fertility and Sterility®surgery unnecessarily. Accordingly, and in keeping with
a consensus statement on research priorities in
endometriosis (9), the last decade has seen much effort
directed at identifying nonsurgical methods of diagnosing
the disease or at least predicting its presence, which can then
inform therapies for associated pelvic pain and/or infertility.
Peripheral biomarkers (e.g., CA-125), endometrial biomarkers
(e.g., endometrial nerve ﬁbre density), and imaging have all
been evaluated (10, 11), showing varying degrees of
accuracy and potential clinical utility. Generally, however,
these procedures predict endometriosis inadequately and are
largely either invasive or semiinvasive themselves.
In recent years, the potential for using clinical infor-
mation to predict endometriosis before surgery has been
explored. In one such study of 90 women undergoing
diagnostic laparoscopy (12), a classiﬁcation tree based on
symptoms, physical examination, and ultrasound ﬁndings
correctly predicted only 38% of nonovarian endometriosis,
an unsurprising ﬁnding given the general limited predictive
accuracy of classiﬁcation trees (13). Another related study
described the development of an externally validated pre-
dictive model of pregnancy rates following a surgical diag-
nosis of endometriosis, but prediction was not based solely
on symptoms. Two other key studies have evaluated the
likelihood of ﬁnding deep inﬁltrating (14) and bladder
(15) endometriosis based on standardized symptom question-
naires, showing ‘‘acceptable’’ and ‘‘excellent’’ diagnostic
value, respectively, for these subtypes. However, the studies
used relatively small samples and, although internal cross-
validation within the data set was attempted in one of the
studies (14) through a bootstrap method, the models have
never been validated in external data sets. Because predictive
models always perform better on data on which they were
generated than on new data, external validation is essential
before implementing predictive models in clinical practice
(16–18).
In addition to the limitations highlighted above, the
global utility of predicting endometriosis clinically is often
hampered by inconsistencies in the deﬁnition of the disease
and associated symptoms across studies and populations
(19). The question as to whether a valid predictive model
based on symptoms associated with endometriosis, generaliz-
able across populations in different countries, can be gener-
ated, led us to initiate the Women's Health Symptom
Survey (WHSS). Its aims were to [1] develop symptom-
basedmodels that predict the likelihood of ﬁnding endometri-
osis at laparoscopy in women who are being investigated for
endometriosis-associated pain and/or infertility and [2] deter-
mine the sensitivity and speciﬁcity of the models in predicting
the likelihood of a diagnosis of endometriosis in a separate
validation sample of women. Although physical examination
plays an important role in the clinical evaluation of symp-
tomatic women, in this study, the models were generated
solely on the basis of symptom/medical history proﬁles and
ultrasound evidence, to allow for standardized evaluation
across centers and countries. Such models, if shown to have
good predictive power, could be used to generate a screening
assessment tool to prioritize women for further surgical
evaluation.VOL. 98 NO. 3 / SEPTEMBER 2012MATERIALS AND METHODS
Study Population
The WHSS was a two-phase (model development/validation),
clinic-based study in 19 hospitals in 13 countries. Between
September 2008 and January 2010, we prospectively re-
cruited 1,396 consecutive pre-menopausal women, aged
18–45, undergoing diagnostic laparoscopy because of at least
one of the following symptoms: dysmenorrhoea (34.0% in
phase I vs. 31.8% in phase II), dyspareunia (12.3% in phase
I vs. 14.5% in phase II), nonmenstrual pelvic pain (36.1% in
phase I vs. 37.0% in phase II), menstrual dyschezia (6.9% in
phase I vs. 8.0% in phase II), or infertility (56.5% in phase I
vs. 47.5% in phase II). Women with a previous surgical diag-
nosis of endometriosis, amenorrhoea or current pregnancy, or
who had taken hormonal medication (including combined
oral contraception) within the previous 3 months, were
excluded.
During the model generating phase I (September 2008 to
June 2009), consenting women who met the inclusion criteria
completed, prior to their scheduled surgery, a 25-item self-
administered questionnaire in their own language (www.
endometriosisfoundation.org/WERF-WHSS-Questionnaire-
English.pdf). During the model validating phase II (July 2009
to January 2010), premenopausal women, aged 18–45 years,
were recruited using the same inclusion and exclusion criteria
as in phase I; they completed the same 25-item questionnaire
before their surgery. The questionnaire incorporated items
to elicit women's past medical, obstetric, and family histories,
as well as items to evaluate the intensity and frequency of
pelvic pain. Pelvic pain intensity was assessed on 11-point
numerical pain rating scales (20) ranging in possible values
from 0 (no pain) to 10 (worst possible pain). The questionnaire
also included standardized questions previously validated
in women with pelvic pain or other symptom groups. These
instruments included [1] the IBS Rome III questionnaire
to identify women with pelvic pain symptoms due to
irritable bowel syndrome (21) and [2] standardized pelvic
pain symptom assessment used in earlier studies in Oxford
(22, 23). The questionnaire also asked for sociodemographic,
lifestyle, and physical attributes. Experienced gynecol-
ogists recorded the laparoscopic ﬁndings in a standard
manner (http://www.endometriosisfoundation.org/WERF-
GSWH-WHSS-surgical-sheet.pdf). For those women who
had preoperative pelvic ultrasound (84.7% and 92.2% of
women in phases I and II, respectively), imaging ﬁndings
were recorded on the surgical sheet.
Cases were deﬁned as women in the study populations
who, at laparoscopy, were found to have endometriosis—
diagnosed on visual evidence alone according to the
European Society of Human Reproduction and Embryology
guideline (1) and staged using the revised American Fertility
Society classiﬁcation: I (minimal), II (mild), III (moderate),
or IV (severe) (24). Controls were women in the study popula-
tions without endometriosis (with or without other diagnoses)
at laparoscopy. The Mid- and South Buckinghamshire
Research Ethics Committee in the United Kingdom approved
the study, followed by approval from all the local ethics
committees.693
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Model generation. Women who had [1] any stage of endo-
metriosis and [2] stage III or IV endometriosis were compared
to controls. To compare cases and controls on categorical
variables, Pearson's c2 tests or the Fisher's exact test were
used where appropriate. Continuous parametric variables
were assessed using the Student's t-test and nonparametric
variables with the Mann-Whitney U test.
As the outcome of interest (presence of any-stage and
stage III or IV endometriosis) was binary in nature, logistic
regression was used for the predictive modeling. The WHSS
questionnaire contained more than 200 variables, which, if
entered into one logistic regression model, would have resulted
in over ﬁtting of models to the data. As a guide, in the ﬁnal
model, the number of degrees of freedom (df) should not exceed
approximately 10% of the number of observations in the
smaller outcome category (25). We therefore employed a tiered
approach to building the predictive model in phase I (Fig. 1).
First, groups of clinically related variables were assessed in
a multivariate logistic regression framework, to assess which
variables within each group showed little or no association
with endometriosis, and could therefore be excluded. For
each group, this was done iteratively by ﬁrst excluding vari-
ables forwhich tests of associationwith endometriosis resulted
in signiﬁcance levels of P>.5, progressing to dropping vari-
ableswithP>.2, resulting in a submodel for each of the groups.
In each group, the goodness of ﬁt of the submodel to the data
was tested using the Hosmer and Lemeshow test (26), whereasFIGURE 1
Model building and validation approach in the WHSS.
Nnoaham. Predicting endometriosis from symptoms. Fertil Steril 2012.
694the drop in Nagelkerke's R2 (assessing the disease variance ex-
plained by the variables in themodel) when removingvariables
was not to exceed 10%. Variables from each of the submodels
were then included in the complete models, which were again
reduced iteratively by considering [1] the Hosmer and Leme-
show test for goodness of ﬁt, [2] the drop in Nagelkerke's
R2 when removing variables, and [3] the signiﬁcance of the as-
sociation of each variable in the model with endometriosis
(dropping variables from P>.5 down to P>.2). This resulted
in best-ﬁtting ﬁnal models for the prediction of any-stage
and stage III and IV endometriosis based on the phase I data.
For each of the two diagnostic outcomes, a model including
and excluding preoperative ultrasound evidence of cysts/nod-
ules was generated (Supplemental Table 1). Final models were
subsequently ﬁtted to phase II data to assess their predictive
performance (seemodel validation below). In addition, reduced
models were generated, which excluded variables in the best-
ﬁtting ﬁnal models that had opposite directions of effect in
phase I and II data sets. These reduced models were also
assessed for performance; thus, a total of eight model types
were generated and assessed (Supplemental Table 1).
Model validation. To illustrate the performance of the derived
predictive models in the phase I population data, and the
relative drop in performance when externally validating in
phase II data, the accuracy of the models in predicting any-
stage and stage III and IV endometriosis was assessed by
analyzing the receiver operating characteristic (ROC) curve
in both phase I and II. The ROC curve displays the relationshipVOL. 98 NO. 3 / SEPTEMBER 2012
TABLE 1
Association results and regression coefﬁcients from best ﬁtting ﬁnal full models for stage III and IV endometriosis excluding (model 5) and including (model 7) ultrasound evidence in phase I, and when
subsequently applied to phase II.
Model Variable
Phase I Phase II
OR (95% CI) P value b OR (95% CI) P value b
Stage III and IV no ultrasound
(model 5)
Surgery/consultation for ovarian cyst* 2.61 (1.35–5.06) .004 0.961 2.65 (1.44–4.86) .002 0.973
Surgery/consultation for infertility* 0.69 (0.39–1.22) .20 0.368 0.66 (0.37–1.19) .16 0.418
Menstrual ﬂowa 1.45 (0.94–2.24) .09 0.372 1.00 (0.68–1.47) .99 0.002
Average cycle length*,b 0.74 (0.57–0.95) .019 0.308 0.77 (0.59–1.01) .057 0.257
Pelvic pain during periods 4.54 (1.60–12.9) .005 1.513 0.60 (0.23–1.52) .28 0.515
Pain on opening bowels during periods* 3.61 (1.85–7.04) < .001 1.283 3.09 (1.39–6.87) .006 1.129
Frequency of period painc 0.68 (0.46–0.99) .043 0.393 1.04 (0.72–1.51) .84 0.040
Period pain limited work/daily activities*,c 1.51 (1.11–2.06) .009 0.412 1.54 (1.11–2.15) .011 0.434
Period pain better after bowel movement*,d 1.32 (1.00–1.74) .052 0.276 1.04 (0.77–1.41) .78 0.043
Stools looser with period pain*,d 0.83 (0.64–1.08) .17 0.183 0.80 (0.60–1.07) .13 0.222
Worst severity of pelvic pain at last
pelvic exam*,g
1.16 (1.02–1.32) .022 0.151 1.14 (0.99–1.32) .06 0.135
Loose stools in generale 1.40 (0.92–2.12) .12 0.334 0.96 (0.64–1.44) .83 0.044
Pelvic pain after urination in general*,f 0.67 (0.42–1.05) .08 0.404 0.86 (0.56–1.34) .51 0.147
Frequency of nocturia in general*,g 0.59 (0.42–0.83) .002 0.528 0.85 (0.63–1.15) .29 0.161
Number of live births*,h 0.59 (0.40–0.89) .011 0.522 0.65 (0.44–0.96) .028 0.429
Ever diagnosed blocked tubes as reason
for subfertility*
0.38 (0.16–0.91) .029 0.966 0.64 (0.31–1.29) .21 0.453
Ovarian cysts (benign) ever diagnosed* 2.35 (1.19–4.62) .014 0.853 3.81 (2.08–6.97) < .001 1.336
Polycystic ovarian syndrome ever diagnosed* 0.34 (0.10–1.14) .08 1.071 0.56 (0.18–1.79) .33 0.577
Family history of asthma in ﬁrst- or second-
degree relative*
0.40 (0.17–0.93) .032 0.924 0.86 (0.39–1.92) .71 0.150
Family history of prostate cancer in ﬁrst- or
second-degree relative
0.23 (0.06–0.84) .027 1.466 1.16 (0.34–3.95) .81 0.150
Asian or Oriental ethnicity*,i 2.73 (1.38–5.41) .004 1.005 2.83 (1.39–5.74) .004 1.039
Black ethnicity*,i 3.71 (1.47–9.38) .006 1.312 4.23 (1.83–9.78) .001 1.441
Other/mixed ethnicityi 0.90 (0.42–1.93) .79 0.104 1.25 (0.55–2.84) .59 0.224
Phase I: Nagelkerke's R2 ¼ 0.47; Hosmer-Lemeshow test ¼ 0.25. Phase II: Nagelkerke's R2 ¼ 0.42; Hosmer-Lemeshow test ¼ 0.94.
Stage III and IV ultrasound
(model 7)
Ultrasound evidence of cyst/nodule 15.4 (8.2–29.0) < .001 2.736 11.2 (6.23–20.1) < .001 2.415
Average cycle length*,b 0.63 (0.47–0.83) .001 0.465 0.79 (0.60–1.06) .11 0.232
Pelvic pain during periods* 1.80 (0.94–3.46) .076 0.589 1.41 (0.80–2.46) .23 0.341
Pain on opening bowels during periods* 2.58 (1.27–5.26) .009 0.949 3.38 (1.53–7.46) .003 1.217
Pain usually approximately same time in
cycle (just after periods)*
2.06 (0.74–5.78) .17 0.725 1.95 (0.63–6.04) .25 0.667
IBS (Rome III)* 3.43 (1.24–9.44) .017 1.231 2.43 (0.76–7.81) .14 0.887
IBS-M (Rome III)* 0.43 (0.13–1.40) .16 0.843 0.47 (0.13–1.76) .26 0.752
Frequency of nocturia in general*,g 0.71 (0.53–0.94) .015 0.350 0.81 (0.64–1.03) .079 0.210
Number of live births*,h 0.59 (0.38–0.92) .019 0.530 0.85 (0.59–1.24) .41 0.159
Ever diagnosed blocked tubes as reason
for subfertility*
0.28 (0.12–0.67) .004 1.270 0.74 (0.38–1.47) .40 0.296
Ovarian cysts (benign) ever diagnosed* 2.82 (1.56–5.09) .001 1.037 3.96 (2.24–7.00) < .001 1.376
Polycystic Ovarian Syndrome ever diagnosed* 0.39 (0.10–1.49) .17 0.941 0.54 (0.17–1.71) .29 0.620
Nnoaham. Predicting endometriosis from symptoms. Fertil Steril 2012.
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ORIGINAL ARTICLE: ENDOMETRIOSISbetween sensitivity and 1-speciﬁcity and the area under the
ROC curve (AUC) depicts how well the model distinguishes
women with and without endometriosis; a model with a
greater AUC has a better-performing risk function. Model
sensitivity, speciﬁcity, and positive and negative likelihood
ratios were also calculated, and the best model cut-off points
were considered to be those that corresponded to the highest
sum of speciﬁcity and sensitivity.
All univariate and logistic regression analyses were done
using the Statistical Package for the Social Sciences 16.0
(SPSS, Inc.); prediction analyses in both phase I and II
populations were conducted within the binary logistic module
in SPLUS 6.0 (TIBCO Software, Inc.); and ROC analysis using
MedCalc 11.6 (MedCalc Software).RESULTS
Description of the Predictive Models
As shown in Supplemental Figure 1, 771 (phase I) and 625
(phase II) of the women recruited met the inclusion criteria
and had complete surgical information at the close of the
study. Among participants, the proportions of cases at centers
varied from 35% in Ibadan to 97% in Guangzhou.
Supplemental Table 2 shows the average age of case and con-
trol women in both phases and the frequency of pathology
found at surgery. Endometriosis was diagnosed in 360
(46.7%) women in phase I and 364 (58.2%) women in phase II.
The results of the best-ﬁtting ﬁnal models for any-stage
and stage III and IV endometriosis, respectively, are shown in
Supplemental Table 3 and Table 1, respectively. The results of
the reduced models (only retaining variables with consistent
evidence in phases I and II [see Methods]) are not shown, but
these variables are highlighted in bold. The full ‘‘any-stage
noultrasound’’model 1 (see Supplemental Table 3) had 26 vari-
ables but 12of these (46%)were dropped in the reducedmodel 2
(see Methods). Similarly, 9 of 23 variables (39%) in the full
‘‘any-stage ultrasound’’ model 3 were dropped in the corre-
sponding reduced model 4. Notably, menstrual dyschezia
(pain on opening bowels during periods) and a medical history
of benign ovarian cysts were most strongly associated with
any-stage endometriosis in models with ultrasound (Phase II
OR ¼ 3.12, 95% CI ¼ 1.07–9.10, P¼ .037, and OR ¼ 2.92,
95% CI¼ 1.35–6.30, P¼ .006, respectively) and without ultra-
sound (Phase II OR ¼ 3.47, 95% CI ¼ 1.40–8.57, P¼ .007, and
OR¼ 4.15, 95% CI ¼ 2.19–7.86, P< .001, respectively). Rectal
bleedingduringmenstruation, IBS (Rome III), unspeciﬁed func-
tional bowel disorder, duration of smoking, subfertility due to
blocked tubes, and ethnicity (Asian/Oriental and other/mixed)
were inconsistently associated with endometriosis in both any-
stage endometriosis models. The any-stage ultrasoundmodel 3
explained substantially more variability in endometriosis than
the any-stage no ultrasound model 1 (Nagelkerke's R2 ¼ 0.54
vs. 0.44 in phase I). Although the any-stage model including
ultrasound (model 3) retained its R2 value of 0.54 in phase II,
its value dropped to 0.30 formodel 1, indicating a better predic-
tive performance of models, including ultrasound evidence.
The full stage III and IV no ultrasound model 5 (Table 1),
had 23 variables, but 6 of these were dropped in the reduced
model 6. In comparison, 3 of 18 variables in the full stage IIIVOL. 98 NO. 3 / SEPTEMBER 2012
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reduced model 8. Menstrual dyschezia, a medical history of
benign ovarian cysts, and Black ethnicity were most strongly
associated with stage III and IV endometriosis, whereas other/
mixed ethnicity was the only variable inconsistently associ-
ated with endometriosis in both any-stage endometriosis
models in phases I and II. Although model 7 including ultra-
sound explained greater variability in diagnosis of stage III
and IV endometriosis than model 5 without ultrasound
(Nagelkerke's R2 ¼ 0.57 vs. 0.47 in phase I), the drop in R2
was comparable for both models (to R2 ¼ 0.51 vs. 0.42). All
four full predictive models ﬁtted the data well as shown by
the Hosmer and Lemeshow test P values (all P>.05).TA
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.Validation of the Predictive Models
All four full models were evaluated for their predictive
performance in the phase II data. As expected, ultrasound
evidence alone showed high sensitivity but very low speciﬁc-
ity in the prediction of any or stage III or IV endometriosis
(Table 2), that is, positive ultrasound evidence was a good pre-
dictor of the presence of endometriosis, but negative evidence
was a very poor predictor of absence of disease. As shown in
Table 2 and Figure 2, the full any-stage no ultrasoundmodel 1
had good discrimination in phase I data (AUC ¼ 84.2, 95%
CI ¼ 81.1–87.0, P< .0001), but its performance was reduced
substantially when applied to the phase II validation data
set (AUC ¼ 68.3, 95% CI ¼ 63.9–72.4, P< .0001). Predictive
ability in phase II data was somewhat improved in the reduced
model 2 to AUC ¼ 72.2 (95% CI ¼ 68.1–76.1, P< .001),
although the optimal model cut-off of 0.59 would provide
a low sensitivity of 54%.
Similarly, the full any-stage ultrasoundmodel 3 had good
discrimination in phase I data (AUC ¼ 87.3, 95% CI ¼ 84.2–
90.0, P< .0001), and although some reduction in its perfor-
mance was evident when applied to phase II data
(AUC ¼ 80.0, 95% CI ¼ 75.6–83.3, P< .0001), this reduction
was not as substantial as for the any-stage no ultrasound
model 1. The corresponding reduced model 4 improved pre-
dictive ability in phase II data to AUC ¼ 85.1 (95%
CI ¼ 81.5–88.2, P< .001), its optimal model cut-off of 0.51
providing a sensitivity of 80% and a speciﬁcity of 77% (cf.
respective values of 0.80, 58% and 89% for the full model).
The full stage III or IV no ultrasound model 5 had
good discrimination in phase I data (AUC ¼ 87.3, 95%
CI ¼ 84.3–89.8, P< .0001) and retained good predictive
power when applied to the phase II data set (AUC ¼ 83.3,
95% CI ¼ 79.6–86.6, P< .0001). Notably, the reduced
model 6 did not offer improvement in model performance
(AUC ¼ 81.1, 95% CI ¼ 77.2–84.6, P< .0001). The reduced
model optimal cut-off was 0.24, with a sensitivity of 74%
and speciﬁcity of 78% (cf. respective values of 0.45, 71%,
and 85% for the full model).
Similarly, the stage III or IV ultrasound model 7 had good
discrimination in both phase I (AUC ¼ 90.8, 95% CI ¼ 88.1–
93.0, P< .0001) and phase II data (AUC ¼ 84.9, 95%
CI ¼ 081.4–88.0, P< .0001). The corresponding reduced
model 8 did not improve model performance in phase II
data (AUC ¼ 85.5, 95% CI ¼ 82.0–88.5, P< .0001). TheVOL. 98 NO. 3 / SEPTEMBER 2012 697
FIGURE 2
Receiver operating characteristic curves for the full models predicting any-stage and stage III or IV endometriosis.
Nnoaham. Predicting endometriosis from symptoms. Fertil Steril 2012.
ORIGINAL ARTICLE: ENDOMETRIOSISreduced model optimal cut-off was 0.29, with a sensitivity of
80% and a speciﬁcity of 80% (cf. respective values of 0.24,
82%, and 76% for the full model).DISCUSSION
In this multicenter study of symptomatic premenopausal
women presenting with symptoms that were potentially
indicative of endometriosis, we show that a combination of
symptom characteristics and variables in the medical history,
with or without ultrasound evidence of cysts/nodules, can
predict the ﬁnding of stage III and IV endometriosis at lapa-
roscopy with reasonably good accuracy. The best-ﬁtting pre-
dictive model included, along with ultrasound evidence,
menstrual dyschezia, ethnicity, and a history of benign ovar-
ian cysts as the variables with the strongest predictive perfor-
mance. These variables are mostly disease risk factors
reported in previous studies. Speciﬁcally, menstrual dysche-
zia is strongly associated with deep inﬁltrating endometriosis,698a severe form of the disease (27), which had a relatively low
prevalence in our clinical population (7.0% in phase I, and
7.8% in phase II). The positive association of stage III
and IV endometriosis with Black ethnicity, however, conﬂicts
with previous reports which suggest that White and Asian
women have a greater risk of disease (28), although these
reports generally relate to any-stage, rather than stage III
and IV, endometriosis.
In this study, we report the development in one sample
population, and validation in another drawn from the same
source population, of models predicting [1] any-stage and
[2] stage III and IV, endometriosis, with or without ultrasound
scan evidence. The ability to predict any-stage endometriosis
in the model excluding ultrasound evidence was generally
poor (AUC ¼ 68.3). Some improvement (AUC ¼ 72.2) could
be gained by removing from the model variables with incon-
sistent association with endometriosis across phase I and II
data, but the external validity of the reduced model would
need to be evaluated in an independent data set. WhenVOL. 98 NO. 3 / SEPTEMBER 2012
Fertility and Sterility®including ultrasound scan evidence, the prediction of
any-stage endometriosis was improved (AUC ¼ 80.0), but
the optimal model cut-off results in a relatively low sensitivity
(58%), which reduces the utility of the model as a potential
clinical screening tool. The poor predictability of any-stage
endometriosis is not surprising given that similar ﬁndings
are reported for models based on serum markers (29),
and stage I (minimal) endometriosis is considered pathoge-
netically to be different to stage III and IV disease (30–33).
In contrast to our ﬁndings, both any-stage and stage III and
IV endometriosis were reported to be predictable from the
medical history of 1,079 prospectively recruited subfertile
women in Portugal (34). However, as the predictive models
were not validated in an independent data set, their ﬁndings
should be interpreted with some caution.
The models predicting stage III and IV endometriosis
(ultrasound evidence) showed much better performance.
However, the model that included ultrasound evidence
showed better performance, which is not surprising given
the value of ultrasound to diagnose ovarian endometriomas
(35)and deep inﬁltrating endometriosis affecting the bowel
(36). Optimal model cut-offs resulted in sensitivities of
70.9% and 82.3%, and speciﬁcities of 84.7% and 75.8%, for
models excluding and including ultrasound evidence, respec-
tively. In contrast to any-stage models, only marginal
improvement could potentially be gained by excluding vari-
ables with inconsistent association with stage III and IV
endometriosis across the data from phases I and II; this rela-
tive consistency in association across phases provided further
evidence of the superior predictability of stage III and IV
endometriosis over ‘‘any stage’’ disease.
The stage III and IV endometriosis models could, in addi-
tion to ultrasound and physical examination, be used to pri-
oritize women presenting with symptoms for laparoscopy in
clinical practice, that is, mirroring the setting in which the
present study was conducted, or to initiate medical therapies
sometimes reserved until a surgical diagnosis of endometri-
osis has been made. To what extent the models have predic-
tive power in other settings (e.g., self-selected women with
pelvic pain symptoms in the general population) is unknown,
and therefore the utility of the tool should not be advocated
for this purpose. Indeed, although identifying a noninvasive
diagnostic test for endometriosis is an explicit priority in en-
dometriosis research, other authors have cautioned that such
a tool could be misappropriated as a population screening
tool for a disease that may not ﬁt a population screening
model (37).
A potential argument against the use of the models to
prioritize symptomatic women for surgery is that a high
prevalence of other pathologies was found among controls
in this study (72%), which could warrant surgical interven-
tion. However, whether surgical intervention would be
deemed appropriate for these pathologies, or indeed whether
they were likely to be the underlying reason for the symptoms
or a coincidental ﬁnding, is a matter for debate. We believe
that the stage III and IV prediction models in particular
are potentially useful clinically, as the likely presence of
moderate/severe disease would be a good basis for prioritiza-
tion of surgical exploration and intervention.VOL. 98 NO. 3 / SEPTEMBER 2012As far aswe know, this is theﬁrst study to use robustmod-
eling techniques for model generation, followed by external
validation to generate and validate symptom-based predictive
models of endometriosis in a large prospectively recruited co-
hort of women across different countries and ethnicities. Pre-
vious attempts, focused on subtypes of endometriosis (13, 14),
have been hampered by small sample sizes (11), and failed to
validate models in populations independent to those from
which model parameters were generated (34). The
enrollment of women from diverse backgrounds according
to a uniform set of criteria potentially addresses issues with
the global utility of clinical prediction of endometriosis
arising from inconsistencies in disease deﬁnition across
studies and population. We invite other research groups to
validate the key models in this paper in additional
populations, as well as in subgroups that may be of speciﬁc
clinical or population-based interest (e.g., those women who
had infertility as the only surgical indication, who had
biopsy-proven disease, or who were of a particular ethnicity).
Although the WHSS was designed to improve on the
limitations of earlier studies, it had itself potential limitations.
First, endometriosis was diagnosed visually, without histo-
logic conﬁrmation, although this followed the European
Society of Human Reproduction and Embryology guideline
(23), based on the premise that negative histology does not
exclude the presence of disease. Consequently, disease status
may have been inappropriately assigned; however, participat-
ing hospitals were experienced in diagnosing endometriosis.
In a separate diagnostic validation study, 29 surgeons from
the participating centers viewed nine standardized videos to
allow, in a blinded manner, the assessment of consistency
in diagnosis and staging of disease. Preliminary analysis sug-
gested substantial inter-rater agreement in disease identiﬁca-
tion and staging (both Fleiss k > 0.60; C. Becker and K. May,
unpublished data). Second, the generation of the models with
reduced numbers of variables was based on both phase I and
phase II data. More parsimonious models are always prefera-
ble (38); however, because they are partly based on phase II
evidence, they would require additional external validation.
Third, although a strength of the study was that results were
generated using data from a wide variety of clinical centers
worldwide covering a range of patient proﬁles, this meant
that the results may have been affected to some extent by
selection bias possibly arising from [1] differential frequency
of concomitant pathologies, in particular the higher pro-
portion of women with nonendometriotic adhesions amongst
controls compared to cases (32.4% vs. 14.7% in phase I), and
[2] the signiﬁcant variations across centers in proportions of
cases in the sample populations. This is another reason why
we call for further independent validation of the models in
additional clinical populations, which are likely to each
have their own unique patient population.
In conclusion, the diagnostic delay, high investigation
costs, and personal suffering associated with endometriosis
might be reduced by access to a screening tool that predicts
endometriosis with good accuracy in women presenting in
a clinical setting. Although prediction of any-stage endome-
triosis is relatively poor, the symptom-based models devel-
oped and validated in this study predict stage III and IV699
ORIGINAL ARTICLE: ENDOMETRIOSISendometriosis with a good degree of accuracy. They suggest
that such a tool might help to prioritize women for surgical
investigation in gynecologic practice.
Acknowledgments: The authors thank all of the women
who participated in the WHSS for their valuable contribu-
tions. The authors are also grateful to all of the clinical and
research assistants at the collaborating centers. K.T.Z. is sup-
ported by a Wellcome Trust Career Development Fellowship
(WT085235/Z/08/Z).Members of the WERF WHSS Consortium
Hany Abdel-Aleem (Assiut University Hospital, Assiut,
Egypt); Mauricio Abr~ao (University of S~ao Paulo, S~ao Paulo,
Brazil); David Adamson (Fertility Physicians of Northern
California, Palo Alto, California, USA); Francisco Carmona
(University of Barcelona, Barcelona, Spain); Thomas
d'Hooghe (University of Leuven, Leuven, Belgium); Carlo de
Cicco Nardone (Universita Cattolica del Sacro Cuore, Rome,
Italy); Fiorenzo de Cicco Nardone (Universita Cattolica del
Sacro Cuore, Rome, Italy); Bukola Fawole (University of
Ibadan, Ibadan, Nigeria); Linda Giudice (University of
California, San Francisco, California); Mark Hornstein
(Brigham and Women's Hospital, Boston, Massachusetts);
Stephen Kennedy (University of Oxford, Oxford, UK); Xishi
Liu (Shanghai Obstetrics and Gynaecology Hospital,
Shanghai, China); Luis Lombardi (CRC Guatemala City,
Guatemala); Xu Min (Guangdong Provincial Hospital of
Traditional Chinese Medicine, Guangzhou, China); Stacey
Missmer (Brigham andWomen's Hospital, Boston, Massachu-
setts); Felice Petraglia (University of Siena, Siena, Italy);
Carlos Petta (State University of Campinas, Campinas, Brazil);
Kanok Seejorn (Khon Kaen University, Khon Kaen, Thailand);
Pamela Stratton (National Institutes of Health, Washington,
DC); Carlos Sueldo (Center for Gynecology and Reproduction,
Buenos Aires, Argentina); and Mary Wingﬁeld (National
Maternity Hospital, Dublin, Ireland).REFERENCES
1. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R,
et al. ESHRE guideline for the diagnosis and treatment of endometriosis.
Hum Reprod 2005;20:2698–704.
2. Hadﬁeld R, Mardon H, Barlow D, Kennedy S. Delay in the diagnosis of endo-
metriosis: a survey of women from the USA and the UK. Hum Reprod 1996;
11:878–80.
3. Husby GK, Haugen RS, MoenMH. Diagnostic delay in womenwith pain and
endometriosis. Acta Obstet Gynecol Scand 2003;82:649–53.
4. Ballard K, Lowton K, Wright J. What's the delay? A qualitative study of
women's experiences of reaching a diagnosis of endometriosis. Fertil Steril
2006;86:1296–301.
5. Nnoaham K, Hummelshoj L, Webster P, D'Hooghe T, De Cicco Nardone F,
De Cicco Nardone, et al. Impact of endometriosis on quality of life and
work productivity: a multi-centre study across 10 countries. Fertil Steril
2011;96:366–73.e8.
6. Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Crosignani PG.
Surgery for endometriosis-associated infertility: a pragmatic approach.
Hum Reprod 2009;24:254–69.
7. Chapron C, Fauconnier A, Gofﬁnet F, Breart G, Dubuisson JB. Laparoscopic
surgery is not inherently dangerous for patients presenting with benign gy-700naecologic pathology. Results of a meta-analysis. Hum Reprod 2002;17:
1334–42.
8. Hoogeveen M, D€orr PJ, Puylaert JBCM. Endometriosis of the rectovaginal
septum: endovaginal US and MRI ﬁndings in two cases. Abdom Imaging
2003;28:897–901.
9. Rogers PAW, D'Hooghe TM, Fazleabas A, Gargett CE, Giudice LC,
Montgomery GW, et al. Priorities for endometriosis research: recommenda-
tions froman International consensusworkshop.ReprodSci 2009;16:335–46.
10. May KE, Villar J, Kirtley S, Kennedy SH, Becker CM. Endometrial alterations in
endometriosis: a systematic review of putative biomarkers. Hum Reprod
Update 2011;17:637–53.
11. May KE, Conduit-Hulbert SA, Villar J, Kirtley S, Kennedy SH, Becker CM.
Peripheral biomarkers of endometriosis: a systematic review. Hum Reprod
Update 2010;16:651–74.
12. Eskenazi B, Warner M, Bonsignore L, Olive D, Samuels S, Vercellini P. Valida-
tion study of nonsurgical diagnosis of endometriosis. Fertil Steril 2001;76:
929–35.
13. Austin P, Lee D. Boosted classiﬁcation trees result in minor to modest
improvement in the accuracy in classifying cardiovascular outcomes com-
pared to conventional classiﬁcation trees. Am J Cardiovasc Dis 2011;1:
1–5.
14. Chapron C, Barakat H, Fritel X, Dubuisson JB, Breart G, Fauconnier A. Pre-
surgical diagnosis of posterior deep inﬁltrating endometriosis based on
a standardized questionnaire. Hum Reprod 2005;20:507–13.
15. Fedele L, Bianchi S, Carmignani L, Berlanda N, Fontana E, Frontino G.
Evaluation of a new questionnaire for the presurgical diagnosis of bladder
endometriosis. Hum Reprod 2007;22:2698–701.
16. Bleeker SE, Moll HA, Steyerberg EW, Donders ART, Derksen-Lubsen G,
Grobbee DE, et al. External validation is necessary in prediction research:
a clinical example. J Clin Epidemiol 2003;56:826–32.
17. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA
microarray data for diagnostic and prognostic classiﬁcation. J Natl Cancer
Inst 2003;95:14–8.
18. Ntzani EE, Ioannidis JPA. Predictive ability of DNA microarrays for cancer
outcomes and correlates: an empirical assessment. Lancet 2003;362:
1439–44.
19. Nnoaham K, Sivananthan S, Hummelshoj L, Jenkinson C, Webster P,
Kennedy S, et al. Multi-center studies of the global impact of endometriosis
and the predictive value of associated symptoms. J Endometriosis 2009;1:
36–45.
20. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA.
Studies with pain rating scales. Ann Rheum Dis 1978;37:378–81.
21. Gwee KA. Irritable bowel syndrome and the Rome III criteria: for better or for
worse? Eur J Gastroenterol Hepatol 2007;19:437–9.
22. Zondervan KT, Yudkin PL, Vessey MP, Jenkinson CP, DawesMG, Barlow DH,
et al. Chronic pelvic pain in the community—symptoms, investigations, and
diagnoses. Am J Obstet Gynecol 2001;184:1149–55.
23. Zondervan KT, Yudkin PL, Vessey MP, Jenkinson CP, DawesMG, Barlow DH,
et al. The community prevalence of chronic pelvic pain in women and
associated illness behaviour. Br J Gen Pract 2001;51:541–7.
24. Revised American Fertility Society classiﬁcation of endometriosis: 1985. Fertil
Steril 1985;43:351–2.
25. Harrell FE, Lee KL, Mark DB.Multivariable prognostic models: issues in devel-
oping models, evaluating assumptions and adequacy, and measuring and
reducing errors. Stat Med 1996;15:361–87.
26. Hosmer D, Lemeshow S. Applied logistic regression. 2nd ed. New York:
Wiley; 2000.
27. Seracchioli R, Mabrouk M, Guerrini M, Manuzzi L, Savelli L, Frasca C, et al.
Dyschezia and posterior deep inﬁltrating endometriosis: analysis of 360
cases. J Minim Invasive Gynecol 2008;15:695–9.
28. Jacoby VL, Fujimoto VY, Giudice LC, KuppermannM,Washington AE. Racial
and ethnic disparities in benign gynecologic conditions and associated
surgeries. Am J Obstet Gynecol 2010;202:514–21.
29. Mol BW, Bayram N, Lijmer JG, Wiegerinck MA, Bongers MY, van der
Veen F, et al. The performance of CA-125 measurement in the de-
tection of endometriosis: a meta-analysis. Fertil Steril 1998;70:
1101–8.VOL. 98 NO. 3 / SEPTEMBER 2012
Fertility and Sterility®30. Koninckx PR, Oosterlynck D, D'Hooghe T, Meuleman C. Deeply inﬁltrating
endometriosis is a disease whereas mild endometriosis could be considered
a non-disease. Ann N Y Acad Sci 1994;734:333–41.
31. Koninckx PR. Is mild endometriosis a condition occurring intermittently in all
women? Hum Reprod 1994;9:2202–5.
32. Brosens IA. Is mild endometriosis a progressive disease? Hum Reprod 1994;
9:2209–11.
33. Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lin J, Lee SH, et al.
Genome-wide association study identiﬁes a locus at 7p15.2 associated
with endometriosis. Nat Genet 2011;43:51–4.
34. Calhaz-Jorge C, Mol BW, Nunes J, Costa AP. Clinical predictive factors for
endometriosis in a Portuguese infertile population. Hum Reprod 2004;19:
2126–31.VOL. 98 NO. 3 / SEPTEMBER 201235. Moore J, Copley S, Morris J, Lindsell D, Golding S, Kennedy S. A systematic
review of the accuracy of ultrasound in the diagnosis of endometriosis.
Ultrasound Obstet Gynecol 2002;20:630–4.
36. Hudelist G, English J, Thomas AE, Tinelli A, Singer CF, Keckstein J. Diagnostic
accuracy of transvaginal ultrasound for non-invasive diagnosis of bowel
endometriosis: systematic review and meta-analysis. Ultrasound Obstet
Gynecol 2011;37:257–63.
37. Somigliana E, Vercellini P, Vigano' P, Benaglia L, Crosignani PG, Fedele L.
Non-invasive diagnosis of endometriosis: the goal or own goal? Hum
Reprod 2010;25:1863–8.
38. McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY. Assessing new
biomarkers and predictive models for use in clinical practice: a clinician's
guide. Arch Intern Med 2008;168:2304–10.701
SUPPLEMENTAL FIGURE 1
Recruitment ﬂowchart for WHSS phases I and II.
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SUPPLEMENTAL TABLE 1
Model types generated based on phase I data alone (‘‘full’’ models) and on additional association information from phase II data (‘‘reduced’’
models).
Diagnosis
Model name
Full model Reduced model
Any-stage endometriosis Any-stage no ultrasound (model 1) Any-stage no ultrasound (model 2)
Any-stage ultrasound (model 3) Any-stage ultrasound (model 4)
Stage III or IV endometriosis Stage III and IV no ultrasound (model 5) Stage III and IV no ultrasound (model 6)
Stage III and IV ultrasound (model 7) Stage III and IV ultrasound (model 8)
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SUPPLEMENTAL TABLE 2
Characteristics of the 1,396 women in the Women's Health Symptom Survey, phases I and II.
Phase I (N[ 771) Phase II (N[ 625)
Cases (n[ 360) Controls (n[ 411) Cases (n[ 364) Controls (n[ 261)
Age (y), mean  SD 31.2  6.0 31.0  6.7 32.4  6.3 32.2  6.2
Ultrasound scan 312 (86.7) 340 (82.7) 341 (93.7) 235 (90.0)
Suggested endometrioma 108 (34.6) 12 (3.5) 165 (48.4) 6 (2.6)
Suggested nodule 17 (5.4) 1 (0.3) 35 (10.3) 11 (4.7)
Pathology observed at surgery 360 (100.0) 298 (72.5) 364 (100.0) 188 (72.0)
Any-stage endometriosis 360 (100.0) 0 (0.0) 364 (100.0) 0 (0.0)
ASRM stage
I 118 (32.8) 0 (0.0) 91 (25.0) 0 (0.0)
II 59 (16.4) 0 (0.0) 39 (10.7) 0 (0.0)
III 89 (24.7) 0 (0.0) 101 (27.7) 0 (0.0)
IV 91 (25.3) 0 (0.0) 128 (35.2) 0 (0.0)
Bladder nodule 16 (4.4) 0 (0.0) 12 (3.3) 0 (0.0)
Cul-de-sac nodule 46 (12.8) 0 (0.0) 61 (16.8) 0 (0.0)
Bowel nodule 25 (6.9) 0 (0.0) 18 (4.9) 0 (0.0)
Fibroids 58 (16.1) 62 (15.1) 77 (21.2) 57 (21.8)
Adhesions 53 (14.7) 133 (32.4) 77 (21.2) 65 (24.9)
Nonendometriotic ovarian cyst 44 (12.2) 91 (22.1) 39 (10.7) 71 (27.2)
Note: Values are n (%) unless noted otherwise.
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SUPPLEMENTAL TABLE 3
Association results and regression coefﬁcients from best-ﬁtting ﬁnal full models for any-stage endometriosis excluding (model 1) and including odel 3) ultrasound evidence in phase I, and when
subsequently applied to phase II.
Model Variable
Phase I
OR (95% CI) P value b
Any-stage no ultrasound (model 1) Surgery/consultation for painful periods* 1.89 (1.15–3.10) .012 0.635
Surgery/consultation for ovarian cyst* 1.63 (0.90–2.95) .11 0.488
Typical duration of periods (days)a 0.84 (0.73–0.96) .010 0.177
Menstrual ﬂowb 1.24 (0.85–1.80) .26 0.214
Pelvic pain during periods* 3.70 (2.22–6.15) < .001 1.307
Pain on opening bowels during periods* 3.85 (1.88–7.91) < .001 1.349
Bleeding on opening bowels during periods 0.11 (0.02–0.63) .013 2.206
Blood in urine during periods* 0.20 (0.03–1.36) .10 1.604
Pelvic pain other times than periods or
intercourse*
2.47 (0.67–9.09) .18 0.902
Time since pelvic pain ﬁrst startedc 0.84 (0.62–1.14) .26 0.175
Worst severity of pelvic pain at last
pelvic exam*,d
1.20 (1.05–1.37) .006 0.184
Incomplete emptying of bladder in general* 0.80 (0.65–0.99) .036 0.221
Pelvic pain after urination in general* 0.76 (0.54–1.08) .12 0.271
IBS-U (Rome III): unspeciﬁed functional
bowel disorder
0.19 (0.04–0.85) .029 1.657
Number of live births*,e 0.57 (0.42–0.76) < .001 0.571
Number of moles*,f 1.32 (0.99–1.75) .058 0.276
Ever diagnosed blocked tubes as reason
for subfertility
0.32 (0.17–0.58) < .001 1.149
Ovarian cysts (benign) ever diagnosed* 2.19 (1.21–3.96) .009 0.784
Polycystic ovarian syndrome ever diagnosed 0.33 (0.15–0.75) .008 1.100
Scoliosis ever diagnosed 3.38 (1.02–11.1) .045 1.218
Family history of endometriosis in ﬁrst-
or second-degree relative*
2.92 (0.99–8.61) .052 1.072
Family history of asthma in ﬁrst- or second-
degree relative
0.42 (0.22–0.80) .009 0.863
Asian or Oriental ethnicityg 0.90 (0.47–1.72) .74 0.108
Black ethnicity*,g 2.02 (0.77–5.29) .15 0.705
Other/mixed ethnicityg 0.70 (0.36–1.36) .30 0.353
Duration of smoking (years)a 0.96 (0.93–0.99) .005 0.043
Phase I: Nagelkerke's R2 ¼ 0.44; Hosmer-Lemeshow test ¼ 0.76. Phase II: Nagelkerke's R2 ¼ 0.30; Hosme
Any-stage ultrasound (model 3) Ultrasound evidence of cyst/nodule* 18.9 (7.5–47.3) < .001 2.939
Surgery/consultation for painful periods* 4.37 (2.28–8.36) < .001 1.474
Surgery/consultation for infertility 0.65 (0.36–1.19) .17 0.428
Surgery/consultation for heavy periods 0.30 (0.13–0.70) .006 1.202
Pain on opening bowels during periods* 5.33 (2.18–13.0) < .001 1.637
Bleeding on opening bowels during periods 0.01 (0.0–0.08) < .001 4.753
Pelvic pain other times than periods
or intercourse*
7.23 (2.18–24.4) .001 1.978
Average severity of pelvic pain*,d 0.79 (0.64–0.98) .031 0.237
Worst severity of pelvic pain at last
pelvic exam*,d
1.25 (1.06–1.48) .010 0.224
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OR (95% CI) P value b
1.97 (1.12–3.47) .019 0.679
1.53 (0.84–2.80) .17 0.427
1.03 (0.89–1.19) .73 0.026
0.93 (0.63–1.37) .70 0.076
1.12 (0.67–1.88) .67 0.112
3.47 (1.40–8.57) .007 1.24
1.88 (0.11–31.1) .66 0.632
0.62 (0.11–3.42) .59 0.471
1.22 (0.29–5.20) .78 0.202
1.06 (0.76–1.48) .74 0.056
1.14 (0.99–1.33) .074 0.134
0.89 (0.71–1.13) .35 0.112
0.54 (0.36–0.82) .004 0.618
3.40 (0.25–47.0) .36 1.22
0.61 (0.44–0.83) .002 0.501
1.23 (0.90–1.68) .19 0.209
0.99 (0.54–1.82) .98 0.009
4.15 (2.19–7.86) < .001 1.42
1.20 (0.45–3.23) .72 0.182
0.80 (0.27–2.36) .69 0220
1.77 (0.67–4.64) .25 0.568
1.31 (0.61–2.86) .49 0.273
1.37 (0.65–2.87) .41 0.314
5.70 (2.53–12.8) < .001 1.74
1.31 (0.60–2.84) .50 0.267
1.02 (0.98–1.06) .42 0.018
r-Lemeshow test ¼ 0.22
122 (27–548) < .001 4.806
1.65 (0.80–3.44) .18 0.503
1.40 (0.72–2.74) .32 0.338
1.18 (0.51–2.75) .70 0.165
3.12 (1.07–9.10) .037 1.137
2.81 (0.14–58.0) .50 1.035
1.16 (0.33–4.09) .82 0.144
0.82 (0.64–1.06) .13 0.196
1.22 (0.98–1.53) .081 0.199
Fertility
and
Sterility®
SUPPLEMENTAL TABLE 3
Continued.
Model Variable
Phase I Phase II
OR (95% CI) P value b OR (95% CI) P value b
Incomplete emptying of bladder in general* 0.62 (0.47–0.80) < .001 0.485 0.84 (0.63–1.13) .25 0.174
IBS-U (Rome III): unspeciﬁed functional
bowel disorder
0.09 (0.01–0.60) .013 2.433 1.86 (0.11–31.5) .67 0.621
Number of live births*,e 0.71 (0.50–1.00) .051 0.346 0.60 (0.40–0.91) .016 0.507
Number of molesf 1.26 (0.90–1.78) .18 0.232 0.98 (0.67–1.42) .91 0.021
Ever diagnosed blocked tubes as reason
for subfertility
0.37 (0.18–0.78) .009 0.993 1.30 (0.66–2.57) .45 0.264
Ovarian cysts (benign) ever diagnosed* 2.74 (1.51–4.95) .001 1.007 2.92 (1.35–6.30) .006 1.072
Scoliosis ever diagnosed* 10.1 (2.14–47.2) .003 2.308 1.16 (0.33–4.08) .82 0.148
Asthma ever diagnosed* 0.31 (0.10–0.94) .039 1.186 0.16 (0.03–0.81) .027 1.863
Family history of ovarian cancer in ﬁrst- or
second-degree relative*
0.28 (0.07–1.06) .06 1.290 0.43 (0.03–5.62) .52 0.851
Family history of endometriosis in ﬁrst- or
second-degree relative*
3.38 (0.69–16.4) .132 1.218 1.54 (0.39–6.11) .54 0.432
Asian or Oriental ethnicityg 0.37 (0.17–0.81) .014 1.003 1.05 (0.42–2.63) .92 0.045
Black ethnicity*,g 2.81 (0.91–8.74) .074 1.034 7.88 (3.03–20.5) < .001 2.064
Other/Mixed ethnicityg 0.53 (0.24–1.14) .10 0.631 1.49 (0.56–3.93) .42 0.396
Duration of smoking (years)a 0.93 (0.89–0.97) < .001 0.073 1.07 (1.02–1.13) .011 0.071
Phase I: Nagelkerke's R2 ¼ 0.54; Hosmer-Lemeshow test ¼ 0.16. Phase II: Nagelkerke's R2 ¼ 0.54; Hosmer-Lemeshow test ¼ 0.84
* Variables retained in the reduced models. Variables in the best-ﬁtting ﬁnal models that had opposite directions of effect in phase I and II data sets were dropped in the reduced models. IBS ¼ irritable bowel syndrome.
a Included as a linear term: OR represents unit change.
b Included as a linear term: OR represents unit change from light to moderate to heavy.
c Included as a linear term: OR represents unit change from no pain to 0–3 months, 4–6 months, 7–12 months, 1–5 years, to 5 years ago.
d Included as a linear term: OR represents unit change from 0 to 10.
e Included as a linear term: OR represents unit change from 0, 1, 2, to 3þ.
f Included as a linear term: OR represents unit change from none, 1–10, 11–50, to 50þ.
g Ethnicity is included as a categorical term, with largest group (white) as reference.
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